Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback